Product Description
It has been well recognized that genomics and proteomics play increasingly important roles in the modern pharmaceutical and healthcare industries. To more efficiently discover drugs, drug companies now increasingly apply these technologies to targeted therapy. Their efforts are leading to the gradual realization of personalized medicines.
On the surface, what drive the gradual realization of personalized medicines are the technologies developed in molecular biomarker and diagnostics. However, it’s the genomics and proteomics that directly facilitate the development of new biomarkers and diagnostics. So the bridges that connect the personalized medicines and genomics/proteomics are the molecular biomarkers and diagnostics. Besides, genomics and proteomics are also increasingly employed in development of translational medicines.
It is therefore appropriate to say that genomics and proteomics have become the new frontier research focuses of the entire pharmaceutical industry in the modern era. They are the fundamental and key technologies for modern drug discovery and development, especially for personalized medicines and translational medicines. Effectively utilizing the technologies to discover more effective drugs has become the high priority to every drug company, whether major pharma or small biotech.
In the booming Chinese biotechnology industry, a growing number of Chinese companies are involved in genomics and proteomics research. They are also diligently applying the technologies to developing biomarkers and new diagnostic products. Moreover, the fast growth of the Chinese economy which makes more Chinese people affordable for better healthcare products and the on-going nationwide healthcare reform which makes better insurance coverage readily available to more Chinese residents, also prompt the fast development and growth of the Chinese genomics, proteomics and all related industries.
The fast growth of the Chinese genomics, proteomics and related industries has thus made not only the Chinese market but also the Chinese companies in the industry so attractive to many foreign companies that are interested in seeking partnership for co-developing or marketing their products in China. The current research and service capability of the Chinese companies, their product portfolios and marketing capabilities all have become the concerning points to these foreign companies. In fact, China is also rapidly emerging as an acceptable destination for genomics- and proteomics-related research.
The report, “Outlook of China Genomics and Proteomics Market – Application in Molecular Biomarker, Diagnostics and Personalized Medicine”, published by JZMed, Inc, a world renowned market research firm specialized in Chinese pharmaceutical and biotechnology industries, has provided the unique insights into the current development states of the Chinese industry.
The report analyzed, both in depth and in detail, the Chinese industry in all aspects including its current industry size and structural composition, research and technical capabilities in genomics and proteomics, product development capabilities in biomarkers and diagnostics, and portfolio distributions of genomic, proteomic and diagnostic products. With detailed analysis of the current market size of the Chinese industry in each area and comparison with their corresponding global markets, the report provides the clear insights into where each sector of this Chinese industry currently stands in the global landscape.
The report also pointed out the current competitive landscape of the Chinese diagnostic industry including the top players among both domestic and multinational companies. Moreover, with detailed discussion and the classifications of diagnostic products in China, the report also outlined detailed procedures of how to register and market IVD products and medical devices in China.
More importantly, based on the in-depth analysis of a series of growth drivers and resistors that would affect the future development of this Chinese industry, the report depicted a clear picture of what the Chinese industry would look like by 2015, including the future market growth of all sectors and their possible shares in the corresponding global markets.
The report is a must-read book to global pharmaceutical and biotechnology companies that are seeking marketing opportunities in China and collaborating with Chinese biotech companies, venture capital investors interested in investment opportunities in the Chinese biotech industry, market research/consultancy companies seeking the information of the Chinese genomics, proteomics, molecular biomarker and diagnostics industries, and even the government agencies of those countries that are interested in learning the current and future development of the Chinese biotechnology industry.